Who are the manufacturers of Panitumumab?

Panitumumab, jointly developed by Amgen and Abgenix in the United States is a research product of a new type of targeted cancer treatment drug epidermal growth factor receptor (EGFr) inhibitor. Panitumumab (formerly ABX-EGF) is the first fully human monoclonal antibody directed against EGFr and is being evaluated as monotherapy or in combination with other agents to treat various types of cancer, including colorectal, lung and renal cancer. Panitumumab is produced by Abgenix's XenoMouse(R) technology, which produces fully human monoclonal antibodies that do not contain murine (mouse) proteins.

As part of this new indication,The FDA approved the first multi-gene, next-generation sequencing-based test to identify the RAS mutation status of a patient's tumor. This companion diagnostic helps physicians identify patients who are more likely to benefit from treatment with panitumumab. Panitumumab has demonstrated a significant overall survival benefit in patients with metastatic colorectal cancer without RAS mutations, providing physicians with a new targeted treatment option.

It is understood that the original version of panitumumab has not yet been launched in China, and therefore it has not been covered by medical insurance. The price of the Hong Kong original version of panitumumab sold in Hong Kong, China100mg/5mL may be around RMB 9,000 (the price may fluctuate due to exchange rates). There are currently no generic drugs of Panitumumab on the market. If a patient has a need to purchase Panitumumab, please consult a medical consultant for specific prices and more drug information.